See the DrugPatentWatch profile for Inrebic
What is Inrebic Prescribing Information?
Inrebic prescribing information is a document that provides comprehensive details about the drug Inrebic (fedratinib). It is intended for healthcare professionals and outlines essential information for its safe and effective use. This includes the drug's indications, dosage, administration, contraindications, warnings and precautions, adverse reactions, drug interactions, and information on clinical pharmacology [1].
What is Inrebic Used For?
Inrebic is approved for the treatment of adults with intermediate-2 or high-risk primary or secondary myelofibrosis (MF) [1]. Myelofibrosis is a serious bone marrow disorder characterized by the scarring of bone marrow tissue, which impairs its ability to produce normal blood cells.
What Are the Key Components of Inrebic Prescribing Information?
The prescribing information for Inrebic covers critical aspects of the drug, such as:
* Indications and Usage: Specifies the approved uses for the medication [1].
* Dosage and Administration: Details how to take Inrebic, including starting doses, dose adjustments, and how to manage missed doses [1].
* Contraindications: Lists situations where the drug should not be used [1].
* Warnings and Precautions: Highlights potential serious risks, such as the risk of serious and fatal encephalopathy, and emphasizes the need for careful monitoring [1].
* Adverse Reactions: Describes common and serious side effects that patients may experience [1].
* Drug Interactions: Identifies other medications that may interact with Inrebic, potentially affecting its efficacy or safety [1].
* Clinical Pharmacology: Explains how the drug works in the body, including its mechanism of action, pharmacokinetics, and pharmacodynamics [1].
* Use in Specific Populations: Provides guidance on using Inrebic in pregnant or breastfeeding women, and in pediatric or geriatric patients [1].
* Overdosage: Offers information on managing cases of excessive Inrebic intake [1].
* Patient Counseling Information: Supplies key points for healthcare providers to discuss with patients regarding Inrebic [1].
What Are the Risks Associated with Inrebic?
A significant risk highlighted in the Inrebic prescribing information is the potential for serious and fatal encephalopathy, characterized by symptoms such as confusion, disorientation, mood changes, and cognitive impairment [1]. Patients receiving Inrebic require close monitoring for neurological symptoms, and dose modifications or discontinuation may be necessary [1]. Other potential risks and serious adverse reactions include gastrointestinal toxicity, cardiac events, and the potential for fetal harm [1].
How is Inrebic Dosed?
The recommended starting dose for Inrebic is 200 mg taken orally once daily [1]. Dosage adjustments are based on blood counts and the presence of specific adverse events. The maximum recommended daily dose is 200 mg [1].
When Does Inrebic Patent Protection Expire?
Information regarding the patent expiry for Inrebic would be available through specialized patent databases. DrugPatentWatch.com provides comprehensive patent information for pharmaceuticals, including expiry dates and patent litigation [2]. Access to such detailed patent landscapes is crucial for understanding market exclusivity and the potential for generic competition.
---
Sources:
[1] Inrebic Prescribing Information. Available at: https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/212108s000,214737s000lbl.pdf
[2] DrugPatentWatch.com. Available at: https://drugpatentwatch.com/